ID
34745
Description
Study ID: 101998 Clinical Study ID: 101998 Study Title: A randomized, double-blind, parallel group, placebo-controlled, single-attack evaluation of the efficacy and tolerability of TREXIMA™ (sumatriptan 85mg/naproxen sodium 500mg)* tablets vs placebo when administered during the mild pain phase of a migraine Patient Level Data Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier Sponsor GlaxoSmithKline Collaborators N/A Phase Phase 3 Study Recruitment Status Completed Generic Name sumatriptan Trade Name Imitrex ,Imiject ,Imigran Study Indication Migraine Disorders This form contains the conclusion of the study it should be filled out at the final visit.
Mots-clés
Versions (2)
- 26/01/2019 26/01/2019 -
- 01/02/2019 01/02/2019 -
Détendeur de droits
GlaxoSmithKline
Téléchargé le
26 janvier 2019
DOI
Pour une demande vous connecter.
Licence
Creative Commons BY-NC 3.0
Modèle Commentaires :
Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.
Groupe Item commentaires pour :
Item commentaires pour :
Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.
Efficacy and Tolerability of TREXIMA Tablets vs. Placebo During Mild Migraine Study ID 101998
Study Conclusion
- StudyEvent: ODM
Description
Study Conclusion
Alias
- UMLS CUI-1
- C1707478
- UMLS CUI-2
- C0008972
Description
If Yes, tick the primary reason for withdrawal
Type de données
text
Alias
- UMLS CUI [1]
- C0422727
Description
Adverse Event: Record details on the Non-Serious Adverse Events or Serious Adverse Event pages as appropriate. If subject did not meet treatment eligibility criteria, ensure ’Clinically significant screening lab values’ and/or ’Clinically significant screening ECG abnormalities’ are ticked.
Type de données
text
Alias
- UMLS CUI [1,1]
- C2349954
- UMLS CUI [1,2]
- C0392360
- UMLS CUI [1,3]
- C0008976
Description
Other Specification
Type de données
text
Alias
- UMLS CUI [1,1]
- C0205394
- UMLS CUI [1,2]
- C2348235
- UMLS CUI [2,1]
- C2349954
- UMLS CUI [2,2]
- C0392360
- UMLS CUI [2,3]
- C0008976
Description
Investigator Comment Log
Alias
- UMLS CUI-1
- C0008961
- UMLS CUI-2
- C0947611
Description
CRF Page Number
Type de données
text
Alias
- UMLS CUI [1,1]
- C1704732
- UMLS CUI [1,2]
- C1516308
Description
Only use this form to record explanatory information on anomalies such as missing data, sponsor waiver of inclusion/exclusion criteria, departures from planned investigational product administration or missed visits.
Type de données
text
Alias
- UMLS CUI [1]
- C0947611
Description
Signature
Alias
- UMLS CUI-1
- C1519316
Description
The Investigator is accountable for CRF data. However, the Principal Investigator may delegate CRF signature authority to a medically qualified Sub-investigator (as indicated on the Site Staff Signature Sheet).
Type de données
text
Alias
- UMLS CUI [1]
- C2346576
Description
Date
Type de données
date
Alias
- UMLS CUI [1]
- C0011008
Description
Investigator's Name
Type de données
text
Alias
- UMLS CUI [1]
- C2826892
Similar models
Study Conclusion
- StudyEvent: ODM
C0011008 (UMLS CUI [2,1])
C0422727 (UMLS CUI [2,2])
C0392360 (UMLS CUI [1,2])
C0008976 (UMLS CUI [1,3])
C2348235 (UMLS CUI [1,2])
C2349954 (UMLS CUI [2,1])
C0392360 (UMLS CUI [2,2])
C0008976 (UMLS CUI [2,3])
C0947611 (UMLS CUI-2)
C1516308 (UMLS CUI [1,2])